The Sporadic Inclusion Body Myositis Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Sporadic Inclusion Body Myositis market Size from 2017 to 2030 segmented by seven major markets.
The report provides a detailed current Sporadic Inclusion Body Myositis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Sporadic inclusion body myositis (sIBM) is an acquired progressive muscle disorder that becomes apparent during adulthood. The symptoms and progression of sIBM vary from one person to another. In most cases, sIBM is characterized by progressive weakness and degeneration (atrophy) of the muscles, especially those of the arms and the legs. sIBM can progress to cause severe disability.
There is no cure for sIBM and the disorder generally does not respond to conventional therapies for autoimmune disorders such as corticosteroids or drugs that suppress the immune system (immunosuppressive drugs). Some individuals have responded to these therapies for a short period of time or to a minor degree (i.e., there is not a full recovery of muscle strength). The specific types of immunosuppressive drugs that have been used to treat individuals with sIBM include azathioprine, methotrexate, cyclosporine, and cyclophosphamide.
Sporadic Inclusion Body Myositis Market Key Facts
-
A male predominance and a prevalence of 1–71 people per million inhabitants has been reported in different populations, rising up to 139 per million among people over 50 years old as per a study conducted by Gang et al (2014).
As per Orphanet, the Prevalence of IBM in the general population ranges from 1:1,000,000 to 1:14,000 but a three-fold increase is observed when considering only a population over 50 years.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market
Key Benefits of Sporadic Inclusion Body Myositis Market Report
-
The market report provides an in-depth analysis of Sporadic Inclusion Body Myositis Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.
-
The report will help in developing business strategies by understanding the Sporadic Inclusion Body Myositis Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.
-
The market report covers the Sporadic Inclusion Body Myositis current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.
-
The report provides a detailed assessment of the Sporadic Inclusion Body Myositis market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors.
Sporadic Inclusion Body Myositis Market
The market size of Sporadic Inclusion Body Myositis is expected to grow during the forecast period owing to the launch of upcoming therapies.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Sporadic Inclusion Body Myositis market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.
The report gives a thorough detail of the Sporadic Inclusion Body Myositis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request for Sample @ Sporadic Inclusion Body Myositis Therapeutics Market Assessment
Sporadic Inclusion Body Myositis Epidemiology
The epidemiology section covers insights about the historical and current Sporadic Inclusion Body Myositis patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Sporadic Inclusion Body Myositis Epidemiology Segmentation
-
Prevalent Cases of Sporadic Inclusion Body Myositis (sIBM)
-
Gender-Specific Prevalent Cases of Sporadic Inclusion Body Myositis (sIBM)
-
Diagnosed and Treatable Cases of Sporadic Inclusion Body Myositis (sIBM)
Sporadic Inclusion Body Myositis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Sporadic Inclusion Body Myositis market or expected to get launched in the market during the study period. The analysis covers Sporadic Inclusion Body Myositis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Sporadic Inclusion Body Myositis Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
The dynamics of the Sporadic Inclusion Body Myositis (sIBM) market is anticipated to change in the coming years owing to the improvement in healthcare spending across the world. Key Companies across the globe are diligently involved in the development of therapies for Sporadic Inclusion Body Myositis. The launch of emerging therapies is expected during the forecast period.
Some of the key companies in the Sporadic Inclusion Body Myositis market include:
-
Orphazyme
-
Novartis
-
Kv1.3 Therapeutics
And many others.
Sporadic Inclusion Body Myositis Therapies covered in the report includes
-
BYM338 (bimagrumab)
-
Dalazatide
-
Arimoclomol
And many others.
The pipeline for Sporadic Inclusion Body Myositis (sIBM) brings a slight positive ray of hope for a better treatment pattern in the market in the upcoming years with the emergence of new therapies in the market. The current scenario also anticipates a positive shift in the market for a study period.
Table of Content
1. Key Insights
2. Executive Summary
3. Sporadic Inclusion Body Myositis Competitive Intelligence Analysis
4. Sporadic Inclusion Body Myositis Market Overview at a Glance
5. Sporadic Inclusion Body Myositis Disease Background and Overview
6. Sporadic Inclusion Body Myositis Patient Journey
7. Sporadic Inclusion Body Myositis Epidemiology and Patient Population
8. Sporadic Inclusion Body Myositis Treatment Algorithm, Current Treatment, and Medical Practices
9. Sporadic Inclusion Body Myositis Unmet Needs
10. Key Endpoints of Sporadic Inclusion Body Myositis Treatment
11. Sporadic Inclusion Body Myositis Marketed Products
12. Sporadic Inclusion Body Myositis Emerging Therapies
13. Sporadic Inclusion Body Myositis Seven Major Market Analysis
14. Attribute Analysis
15. Sporadic Inclusion Body Myositis Market Outlook (7 major markets)
16. Sporadic Inclusion Body Myositis Access and Reimbursement Overview
17. KOL Views on the Sporadic Inclusion Body Myositis Market.
18. Sporadic Inclusion Body Myositis Market Drivers
19. Sporadic Inclusion Body Myositis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Get FREE sample copy at:
https://www.delveinsight.com/sample-request/sporadic-inclusion-body-myositis-sibm-market
Latest Reports By DelveInsight
Sporadic Inclusion Body Myositis (sIBM) Pipeline Insights
Sporadic Inclusion Body Myositis Pipeline Insight, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the market.
Muscle Atrophy/ Wasting Syndrome Market
DelveInsight's "Muscle Atrophy/ Wasting Syndrome Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Muscle Atrophy/ Wasting Syndrome market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
